HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Open Russian OTC Market Would Come With Challenges

This article was originally published in The Tan Sheet

Executive Summary

Expanding nonprescription drug sales in Russia from pharmacies to grocery stores would open doors to new sales, but the huge emerging market presents significant hurdles to firms looking to fully capitalize on the opportunity

You may also be interested in...



Reader's Digest poll reveals high use of diet pills in China

China not only has the largest population at 1.3 billion, it also has the largest percentage of diet pill users - 37 percent - a 16-country survey of 16,000 people in the February issue of Reader's Digest shows. The report out Jan. 15 also says 30 percent of people in Brazil take diet pills, as do 24 percent of people in Russia and 23 percent in Mexico. China and Russia are emerging markets of increasing interest to drug and supplement firms, but entering these markets poses significant challenges including regulatory irregularities and stringent review processes (1"The Tan Sheet" Sept. 16, 2009 and 2"The Tan Sheet" Nov. 30, 2009)

Sanofi Includes OTCs As Key Touchstone On Growth Chart

Sanofi-Aventis' planned dedicated OTC division will be a key component in the firm's efforts to better focus on maximizing product opportunities and identifying new acquisition targets

Russia’s Emerging OTC Market Holds Problems As Well As Promise

Russia's rapidly growing over-the-counter market offers pharmaceutical companies a chance to expand their business, but its complex regulations and lengthy registration timelines may hinder entry

Related Content

Topics

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel